Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Bristol-Myers Squibb
Allist Pharmaceuticals, Inc.
Merck Sharp & Dohme LLC
Revolution Medicines, Inc.
D3 Bio (Wuxi) Co., Ltd
M.D. Anderson Cancer Center
Novartis
H. Lee Moffitt Cancer Center and Research Institute
Verastem, Inc.
M.D. Anderson Cancer Center
Novartis
Revolution Medicines, Inc.
FBD Biologics Limited
Sanofi
Jacobio Pharmaceuticals Co., Ltd.
M.D. Anderson Cancer Center
Bristol-Myers Squibb
University of Miami
Genfleet Therapeutics (Shanghai) Inc.
M.D. Anderson Cancer Center
University of Chicago
Chang Gung Memorial Hospital
Mirati Therapeutics Inc.
Eli Lilly and Company
Genfleet Therapeutics (Shanghai) Inc.
Sanofi
Bristol-Myers Squibb
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Sun Yat-sen University
Hummingbird Bioscience
Nektar Therapeutics
Menarini Group
NuCana plc
HiberCell, Inc.
InventisBio Co., Ltd
ImmunityBio, Inc.
ImmunityBio, Inc.
Erasca, Inc.
ImmunityBio, Inc.
GlaxoSmithKline
Zhejiang Cancer Hospital
Washington University School of Medicine
Pharmacyclics LLC.
University of Alabama at Birmingham
Innate Pharma
Sun Yat-sen University
Roswell Park Cancer Institute
Weill Medical College of Cornell University
Eisai Inc.